New heart valve aims for better Long-Term results

NCT ID NCT06420830

Recruiting now Disease control Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 150 people who receive a new type of heart valve (SAPIEN 3 Ultra RESILIA) to see how well it works over time. The valve has special features to prevent calcium buildup and improve durability. Researchers will use echocardiograms to measure valve function and check for leaks or other problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAPIEN 3 Ultra RESILIA valve (a replacement heart valve)
What this could lead to: If successful, this could show that the new valve lasts longer and works better than older versions, improving long-term outcomes for people with severe aortic stenosis.
What could go wrong: This is an observational registry, not a randomized trial, so results may not prove the valve is better. Valve durability can only be assessed over many years, and this study may not be long enough to see clear differences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS TRANSCATHETER AORTIC VALVE REPLACEMENT

Contacts and locations

Locations

IUCPQ
RECRUITING

Québec, Quebec, G1V 4G5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.